Sarcoidosis-associated pulmonary hypertension: Acute vasoresponsiveness to inhaled nitric oxide and the relation to long-term effect of sildenafil

Clinical Respiratory Journal

Volumn 3, Issue 4, 2009, Pages 207-213

  Milman, Nils ^a   Svendsen, Claus Bo ^a   Iversen, Martin ^a   Videbæk, Regitze ^a   Carlsen, Jørn ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Nitric oxide; Pulmonary; Pulmonary hypertension; Sarcoidosis; Sildenafil

Indexed keywords

ILOPROST; NITRIC OXIDE; SILDENAFIL; VASODILATOR AGENT;

ACUTE DISEASE; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; DYSPNEA; FEMALE; HEART CATHETERIZATION; HUMAN; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SARCOIDOSIS;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADULT; BRONCHODILATOR AGENTS; CHI-SQUARE DISTRIBUTION; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NITRIC OXIDE; PIPERAZINES; PURINES; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SARCOIDOSIS; STATISTICS, NONPARAMETRIC; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 70349238778     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/j.1752-699X.2008.00120.x     Document Type: Article

References (29)

1. Foley RJ, Metersky ML. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan. Respiration. 2008 75 (2 211 214.
2. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004 25 (24 2243 2278.
3. Gluskowski J, Hawrylkiewicz I, Zych D, Wojtczak A, Zielinski J. Pulmonary haemodynamics at rest and during exercise in patients with sarcoidosis. Respiration. 1984 46 (1 26 32.
4. Handa T, Nagai S, Miki S, Fushimi Y, Ohta K, Mishima M, Izumi T. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest. 2006 129 (5 1246 1252.
5. Milman N, Burton CM, Iversen M, Videbaek R, Jensen CV, Carlsen J. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J Heart Lung Transplant. 2008 27 (3 329 334.
6. Preston IR, Klinger JR, Landzberg MJ, Houtchens J, Nelson D, Hill NS. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest. 2001 120 (3 866 872.
7. Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J. 2005 25 (5 783 788.
8. Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest. 2005 128 (3 1483 1489.
9. Nunes H, Humbert M, Capron F, Brauner M, Sitbon O, Battesti JP, Simonneau G, Valeyre D. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax. 2006 61 (1 68 74.
10. Milman N, Burton C, Andersen CB, Carlsen J, Iversen M. Lung transplantation for end-stage pulmonary sarcoidosis: outcome in a series of seven consecutive patients. Sarcoidosis Vasc Diffuse Lung Dis. 2005 22 (3 222 228.
11. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007 131 (6 1917 1928.
12. Damuth TE, Bower JS, Cho K, Dantzker DR. Major pulmonary artery stenosis causing pulmonary hypertension in sarcoidosis. Chest. 1980 78 (6 888 891.
13. Smith LJ, Lawrence JB, Katzenstein AA. Vascular sarcoidosis: a rare cause of pulmonary hypertension. Am J Med Sci. 1983 285 (1 38 44.
14. Tayal S, Voelkel NF, Rai PR, Cool CD. Sarcoidois and pulmonary hypertension - a case report. Eur J Med Res. 2006 11 (5 194 197.
15. Castaner E, Gallardo X, Pallardo Y, Branera J, Cabezuelo MA, Mata JM. Diseases affecting the peribronchovascular interstitium: CT findings and pathologic correlation. Curr Probl Diagn Radiol. 2005 34 (2 63 75.
16. Hennebicque AS, Nunes H, Brillet PY, Moulahi H, Valeyre D, Brauner MW. CT findings in severe thoracic sarcoidosis. Eur Radiol. 2005 15 (1 23 30.
17. Takemura T, Matsui Y, Saiki S, Mikami R. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. Hum Pathol. 1992 23 (11 1216 1223.
18. Rosen Y, Moon S, Huang CT, Gourin A, Lyons HA. Granulomatous pulmonary angiitis in sarcoidosis. Arch Pathol Lab Med. 1977 101 (4 170 174.
19. Mitchell DN, Scadding JG. Sarcoidosis. Am Rev Respir Dis. 1974 110 (6 774 802.
20. Byg KE, Milman N, Hansen S. Sarcoidosis in Denmark 1980-1994. A registry-based incidence study comprising 5536 patients. Sarcoidosis Vasc Diffuse Lung Dis. 2003 20 (1 46 52.
21. Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004 170 (12 1324 1330.
22. Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest. 2006 130 (5 1481 1488.
23. Letizia C, Danese A, Reale MG, Caliumi C, Delfini E, Subioli S, Cerci S, D'Erasmo E. Plasma levels of endothelin-1 increase in patients with sarcoidosis and fall after disease remission. Panminerva Med. 2001 43 (4 257 261.
24. Terashita K, Kato S, Sata M, Inoue S, Nakamura H, Tomoike H. Increased endothelin-1 levels of BAL fluid in patients with pulmonary sarcoidosis. Respirology. 2006 11 (2 145 151.
25. Busch T, Petersen B, Deja M, Donaubauer B, Laudi S, Jaumann S, Bercker S, Boemke W, Kaisers U. Endothelin-1 influences the efficacy of inhaled nitric oxide in experimental acute lung injury. Exp Biol Med. 2006 231 (6 974 978.
26. Bevec D, inventor. Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis. USA patent application no. 20060241028, Application date 2003, Jun 5.
27. Mucke HA. Pulmonary arterial hypertension: on the way to a manageable disease. Curr Opin Investig Drugs. 2008 9 (9 957 962.
28. Polson JB, Strada SJ. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 1996 36 : 403 427.
29. Tantini B, Manes A, Fiumana E, Pignatti C, Guarnieri C, Zannoli R, Md AB, Galie N. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol. 2005 100 (2 131 138.